SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Tokyo Joe's Cafe / Anything goes -- Ignore unavailable to you. Want to Upgrade?


To: Zakattack who wrote (16682)5/12/1998 11:13:00 AM
From: Brett Fleischman  Read Replies (1) | Respond to of 34592
 
Zak,
Nice volume, price should follow shortly.

What is the float? Can't find it.

Brett



To: Zakattack who wrote (16682)5/12/1998 11:13:00 AM
From: Scott A. Trapp  Read Replies (1) | Respond to of 34592
 
Paramount Financial Corporation Announces First Quarter Results

May 12, 1998 10:53 AM

JERICHO, N.Y., May 12 /PRNewswire/ -- Paramount Financial Corporation PARA today announced results for the three months ended March 31, 1998.

The Company reported a consolidated net loss of $33,000 for the first quarter of 1998. This represents a significant improvement over the fourth quarter of 1997 for which the Company reported a net loss of $422,000. For the three months ended March 31, 1997, the Company reported net income of $71,760. The results for the three months ended March 31, 1998 include the Company's two wholly owned subsidiaries, Paratech Resources, Inc. and Deltaforce Personnel Services, Inc. (which the Company acquired in January of 1998). Although Paratech was in existence during the quarter ended March 1997, it did not make as significant a contribution to the Company's gross revenue, expenses or results from operations for that period as it did during the first quarter of 1998. In addition, the Company's results continue to be subject to quarterly fluctuations based on the nature and timing of particular sales and lease transactions.

Total revenue for the first quarter of 1998 was $16.2 million, up 300% from the previous year. The increase in revenue from 1997 to 1998 is a result of the Company's re-marketing efforts with respect to its lease portfolio and the sales at Paratech and Deltaforce.

According to Glenn Nortman, Chief Executive of Paramount, "During the first quarter of 1998, we continued with our long term diversification and growth plans at Paramount. This included the acquisition of Deltaforce, and the ongoing expansion of Paratech. These two companies, when combined with our core leasing operations, provide us with a significant base of products and services to offer to a growing list of clients."

Paramount Financial Corporation is a comprehensive asset management and business solution provider, offering customers a wide range of integrated services, including lease finance, information technology consulting, network design and implementation and staffing services. The Company was formed in 1991 and contains two wholly owned subsidiaries, Paratech Resources, Inc. and as of January 1998, Deltaforce Personnel Services, Inc. The Company's stock is traded on the Nasdaq stock exchange under the symbol PARA.

Statements contained in this press release which are not historical facts are forward-looking statements. The forward-looking statements in this press release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements made herein contain a number of risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, the specific factors impacting the Company's business, including increased competition; the availability of computer equipment; the ability of the Company to expand its operations and attract and retain qualified sales representatives experienced in the purchase, sale and lease of new and used computer equipment; technological obsolescence of the Company's portfolio of computer equipment; and general economic conditions.

PARAMOUNT FINANCIAL CORPORATION
SUMMARY OF OPERATIONS
THREE MONTHS ENDED MARCH 31,

1998 1997

Sales revenue $14,481,462 $936,239
Lease revenue 1,506,328 2,609,347
Fee, interest and
other income 219,927 500,875
Total revenues 16,207,717 4,046,461

Cost of sales 13,788,191 775,144
Lease expense 1,443,175 2,449,082
Selling, general and
administrative 1,031,907 702,636
Total cost and expenses 16,263,273 3,926,862

Income (Loss) before
provision for income taxes (55,556) 119,599
Provision (Benefit) for
income taxes (22,222) 47,839
Net income (Loss) $(33,334) $71,760

Income (Loss) per share $(0.00) $0.01

Weighted average
common shares outstanding 7,914,000 7,990,000

SOURCE Paramount Financial Corporation



To: Zakattack who wrote (16682)5/12/1998 11:16:00 AM
From: Big Dog  Read Replies (3) | Respond to of 34592
 
SRGN here we go. A buy out and it is just getting noticed. Volume is racing. I am getting in now.

BIG DOG

Monday May 11, 6:55 pm Eastern Time
Ligand to buy Seragen
SAN DIEGO, May 11 (Reuters) - Ligand Pharmaceuticals Inc Monday said Monday it plans to buy Seragen Inc in a deal worth up to $67 million which it said will boost earnings from 1999 onwards.
The company said in a statement it will pay for Hopkinton, Mass.-based Seragen in two stages.

Ligand will pay $30 million, $4 million in cash and $26 million of Ligand shares when the deal closes during the third quarter. Seragen's shareholders will receive about 0.036 of a share of Ligand stock for every share of Seragen held. The remainder of the $30 million will be used to settle claims of Seragen's creditors and preferred shareholders.

Ligand will also pay an additional $37 million payment in cash and/or Ligand shares to be paid six months after U.S. Food and Drug Administration clearance to market ONTAK for cutaneous T-cell lymphoma. The $37 million payment will not be made if ONTAK is not cleared by the FDA within two years of the initial closing.

Ligand also said it has agreed to buy substantially all the assets of Marathon Biopharmaceuticals, which provides manufacturing and development services to Seragen, for $5 million with an extra $3 million after FDA approval of ONTAK.

Ligand also signed an agreement with Eli Lilly and Co (LLY - news) under which Lilly will assign to Ligand Lilly's rights and obligations under its agreements with Seragen, including its rights to ONTAK.

Ligand will pay Lilly up to $10 million, payable in cash or Ligand stock in potential milestone payments if ONTAK is approved by the FDA. Upon certain other events, Lilly could receive an additional $10 million in milestones.

''The transfer of product rights from Lilly, the merger with Seragen, and the acquisition of Marathon consolidate important rights to ONTAK previously held by Lilly, Seragen and Ligand,'' said Ligand Chairman David Robinson.

''We believe that the net effect, following closing of the merger, transfer of ONTAK rights from Lilly to Ligand, and launch of ONTAK following regulatory approval, is significantly accretive to Ligand earnings in 1999 and beyond,'' he said.

The merger of Ligand and Seragen has been approved by the board of both comapnies and Seragen shareholders have delivered irrevocable proxies representing between 55 and 59 percent of shares.

In February the FDA informed Seragen it had given ONTAK a ''priority review'' designation.

--------------------------------------------------------------------------------



To: Zakattack who wrote (16682)5/12/1998 1:54:00 PM
From: Land Shark  Respond to of 34592
 
Reputations and company mission statements (especially) don't
pay the rent. Profit/loss statements do (even on paper). I'm staying
away from this one.